companies / brainever-com
Generated UTC · publication cutoff 2026-11-09
Insufficient cited evidence for a two-sentence summary.
verified=2026-05-02 json
| total_raised | 38,772,00038.8M | ○ |
|---|---|---|
| founded | 2018 | |
| hq | Paris, France | |
| industry | unknown | |
| stage | series-b+ |
Clinical-stage biotech developing homeoprotein-based therapies for ALS, Parkinson's and retinal disease. Built for patients with major neurodegenerative diseases lacking disease-modifying treatments. Lead candidate BREN02 (Engrailed 1) leverages founder Alain Prochiantz's discovery that developmental homeoproteins remain active throughout life.
No cited completed company acquisition recorded.
Dated disclosures. Customer relationships and classifications are historical; ARR is separate from revenue.
No cited disclosure recorded: named customer, disclosed revenue, ARR, count, B2B / B2C, sector, go-to-market.
No cited valuation with an explicit basis is recorded.
Historical post-money / actual annual or stated TTM revenue. Same currency; economic valuation date within 90 days of revenue period end, inclusive. No FX, ARR, annualized revenue, estimates or projections. Conflicts and ambiguous ties are withheld.
No qualifying pair recorded.
| date | type | amount | lead | src |
|---|---|---|---|---|
| 2025-07-01 | seed | 35,640,00035.6M | null | ○ |
| fact | status | src |
|---|---|---|
| Seed, $35.6M | attributed | ○ |
| existence | self-reported | WEB |
| description | self-reported | WEB |